

**Beneficiary Advisory Panel Handout**  
**Uniform Formulary Decisions**  
**12 Jan 2012**

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review

**Table 1: Depression & Non-Opioid Pain Syndrome Agents**

Subclass	Formulary Status	Generic (Brand), Manufacturer	Generic available
GABA Analogs	Formulary	Gabapentin (Neurontin)	Y
	Non-Formulary Step Therapy	Pregabalin (Lyrica) <sup>4</sup> Pfizer	N
Selective Serotonin Reuptake Inhibitors (SSRIs)	Formulary	Citalopram (Celexa)	Y
	Formulary	Fluoxetine (Prozac)	Y
	Formulary	Fluvoxamine (Luvox)	Y
	Formulary	Paroxetine HCl (Paxil)	Y
	Formulary	Paroxetine HCl CR (Paxil CR)	Y
	Formulary	Paroxetine mesylate (Pexeva) Synthon	N
	Formulary	Sertraline (Zoloft)	Y
	Non-Formulary	Escitalopram* (Lexapro) Forest	N
	Non-Formulary	Fluoxetine weekly caps* (Prozac Weekly)	Y
	Non-Formulary	Fluoxetine* (Sarafem)	Y
Serotonin – Norepinephrine Reuptake Inhibitors (SNRIs)	Formulary	Venlafaxine (Effexor)	Y
	Formulary	Venlafaxine ER (Effexor XR)	Y
	Non-Formulary/ Step Therapy	Duloxetine (Cymbalta) <sup>2</sup> Eli Lilly	N
	Non-Formulary/ Step Therapy	Desvenlafaxine (Pristiq) <sup>1</sup> Pfizer	N
	Non-Formulary/ Step Therapy	Milnacipran (Savella) <sup>3</sup> Forrest	N
Serotonin-2 Antagonist/Reuptake Inhibitors (SARIs)	Formulary	Nefazodone (Serzone) generic only	Y
	Formulary	Trazodone (Desyrel)	Y
	Non-Formulary	Trazodone ER (Oleptro) Labopharm	N
Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs)	Formulary	Bupropion (Wellbutrin)	Y
	Formulary	Bupropion SR (Wellbutrin SR)	Y
	Formulary	Bupropion XL (Wellbutrin XL)	Y
	Non-Formulary	Bupropion HBr** (Aplenzin) Sanofi Aventis	N
Alpha-2 Receptor Antagonists (A-2RAs)	Formulary	Mirtazapine tablets and ODT (Remeron; Remeron Sol Tab)	Y
Serotonin-1a Partial Agonist/Reuptake Inhibitors	Non-Formulary	Vilazodone (Viibryd) Forest	N
Tricyclic Antidepressants (TCAs)	Formulary	Amitriptyline (Elavil)	Y
	Formulary	Desipramine (Norpramin)	Y
	Formulary	Doxepin (Sinequan)	Y
	Formulary	Imipramine (Tofranil)	Y
	Formulary	Nortriptyline (Pamelor)	Y
	Formulary	Protriptyline (Vivactil)	Y
<b>Recommended : 60-day implementation period</b>			

1 Desvenlafaxine (Pristiq) is non-formulary and non-step preferred. All new users of Pristiq are required to try venlafaxine.

2 Duloxetine (Cymbalta) is non-formulary and non-step preferred. All new users of Cymbalta are required to try an SSRI, SNRI, TCA, mirtazapine, bupropion, trazodone, MAOI, cyclobenzaprine, milnacipran (Savella), gabapentin, or pregabalin (Lyrica).

3 Milnacipran (Savella) is non-formulary and non-step preferred. All new users of Savella are required to try an SNRI, TCA, cyclobenzaprine, gabapentin or pregabalin (Lyrica).

4 Pregabalin (Lyrica) is non-formulary and non-step preferred. All new users of Lyrica are required to try gabapentin.

\* Non-formulary; status of Lexapro, Sarafem, and Prozac Weekly, will change to formulary when cost-effective generics are available

\*\*HBr: hydrogen bromide

**Figure1: Subclass Utilization in 30 day equivalents at All Points of Service**




Figure 2: SNRI Subclass Utilization in 30 day equivalents at All Points of Service




Figure 3: SSRI Utilization in 30 day equivalents at All Points of Service




Figure 4: GABA Utilization in 30 day equivalents at All Points of Service




Table 2: Short Acting Beta Agonists (SABAs)

Formulary Status Implementation Period	Generic Name (Brand)	Formulation	Generic
Formulary	Albuterol solution (Accuneb, generics)	inhalation solution	Yes
	Levalbuterol solution (Xopenex)	inhalation solution	Yes (1.25 mg strength only)
	Albuterol inhaler (Proair HFA, Proventil HFA, Ventolin HFA)	metered dose inhaler	No
	Levalbuterol inhaler (Xopenex)	metered dose inhaler	No
Non-Formulary	Pirbuterol CFC inhaler (Maxair)*	metered dose inhaler	No
Recommended implementation period	N/A – Maxair currently NF		

\* Pirbuterol (Maxair) will be commercially available until December 2013

CFC: chlorofluorocarbon

HFA: hydrofluoroalkane

Figure 5: SABA Metered Dose Inhaler Utilization - Canisters at All Points of Service




Table 3: Phosphodiesterase Type-5 (PDE-5) Inhibitors for Erectile Dysfunction

UF recommendation	Generic Drug Name (Brand)	Generic Available
UF- Step Preferred	Sildenafil (Viagra)	No
Non-Formulary/Step Therapy	Vardenafil (Levitra) <sup>1</sup>	No
	Vardenafil ODT (Staxyn) <sup>1</sup>	No
	Tadalafil (Cialis) <sup>1</sup>	No
Recommended implementation period	60 days	

1: Vardenafil (Levitra), vardenafil ODT (Staxyn) and tadalafil (Cialis) are non-formulary and non-step preferred. All new users of Levitra, Staxyn, or Cialis are required to try sildenafil (Viagra)

ODT: orally dissolving tablet

Figure 6: PDE5 Utilization (Tot Qty Dispensed) – All POS





Table 4: Newly Approved Drugs - Risedronate Delayed Release Tablets (Atelvia); Osteoporosis Drugs (reviewed in June 2008)

UF Status / Implementation Period	Generic Name (Brand)	Generics Available?
Formulary	<b>Bisphosphonates</b>	
	Alendronate (Fosamax)	Yes
	Alendronate / vitamin D (Fosamax plus D)	No
	Ibandronate (Boniva)	No
	Risedronate (Actonel)	No
	Risedronate / calcium (Actonel with calcium)	No
	<b>Selective Estrogen Receptor Modulators (SERMs)</b>	
	Raloxifene (Evista)	No
	<b>Parathyroid Hormone derivatives</b>	
	Teriparatide (Forteo) injection	No
	<b>Calcitonins</b>	
Recombinant calcitonin (Fortical) nasal spray	No	
Non-Formulary	Calcitonin-salmon (Miacalcin) nasal spray	No
	<b>Risedronate delayed release tablets (Atelvia)</b>	<b>No</b>
Recommended implementation period	60 days for Risedronate delayed release (Atelvia)	

**Figure 7: Biphosphonate Sub-Class Utilization in 30 day equivalents in all Points of Service**





**Table 5—Table of Implementation Status of UF Recommendations/Decisions Summary Table**

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Step Therapy	
				MTF	Retail	Mail Order			
Nov 2011	Depression & Non-Opioid Pain Syndromes	Trazodone ER (Oleptro)	470	0	420	50	60 days	N/A	
		Vilazodone (Viibryd)	1806	13	210	1583			
		Duloxetine (Cymbalta) - remains NF - 18K beneficiaries will be affected by the step annually						SSRIs, SNRIs (except milnacipran), TCAs, mirtazapine, bupropion, SARIs, MAOIs	
		Milnacipran (Savella) - remains NF - 2K beneficiaries will be affected by the step annually							
		Pregabalin (Lyrica) - remains NF - 33K beneficiaries will be affected by the step annually							Gabapentin
		Pristiq (remains NF) remains NF - 11K beneficiaries will be affected by the step annually							Venlafaxine
Nov 2011	PDE-5s	Vardenafil (Levitra), Vardenafil ODT (Saxyn), Tadalafil (Cialis)	120K	71K	11K	38K	60 days	Viagra	
Nov 2011	Short-Acting Beta Agonists	Pirbuterol (Maxair) metered dose inhaler	N/A (Maxair currently NF)					N/A	
Nov 2011	Osteoporosis Drugs (June 2008)	Risedronate delayed release (Atelvia) (Nov 2011)	3047	6	2163	878	60 days	N/A	